Literature DB >> 6443765

Epidemiology of infections due to Pseudomonas aeruginosa.

A J Morrison, R P Wenzel.   

Abstract

Pseudomonas aeruginosa is responsible for an increasing proportion of infections acquired in the modern hospital setting. It accounts for 8.5% of all nosocomial infections and has an attack rate of 36 infections per 10,000 hospital discharges. P. aeruginosa represents the single most frequently isolated pathogen in patients with nosocomial pneumonia and burn-wound infections. The organism's bioepidemiology is linked to its ability to thrive in marginal econiches, and its ascendency as a nosocomial pathogen parallels the evolution of high-technology intensive care units, the large numbers of immunocompromised patients, and the liberal use of antibiotics. The reservoirs and modes of transmission for this organism are reviewed along with recent studies aimed at the prevention of both colonization and infection by this organism.

Entities:  

Mesh:

Year:  1984        PMID: 6443765     DOI: 10.1093/clinids/6.supplement_3.s627

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  65 in total

1.  Pharmacodynamic parameters of aminoglycosides and their effect on exoenzymes of Pseudomonas aeruginosa.

Authors:  A Hostacká
Journal:  Folia Microbiol (Praha)       Date:  1996       Impact factor: 2.099

2.  Characteristics of Pseudomonas aeruginosa strains causing septicemia in a Spanish hospital 1981-1990.

Authors:  F Vázquez; M C Mendoza; M H Villar; A Vindel; F J Méndez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-08       Impact factor: 3.267

3.  Role of macrophage chemoattractant protein-1 in acute inflammation after lung contusion.

Authors:  Madathilparambil V Suresh; Bi Yu; David Machado-Aranda; Matthew D Bender; Laura Ochoa-Frongia; Jadwiga D Helinski; Bruce A Davidson; Paul R Knight; Cory M Hogaboam; Bethany B Moore; Krishnan Raghavendran
Journal:  Am J Respir Cell Mol Biol       Date:  2012-01-26       Impact factor: 6.914

4.  Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact.

Authors:  Valerie Aloush; Shiri Navon-Venezia; Yardena Seigman-Igra; Shaltiel Cabili; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

5.  Use of pulsed-field gel electrophoresis as an epidemiologic tool during an outbreak of Pseudomonas aeruginosa lung infections in an intensive care unit.

Authors:  D Talon; G Capellier; A Boillot; Y Michel-Briand
Journal:  Intensive Care Med       Date:  1995-12       Impact factor: 17.440

6.  Synergy of drug combinations in treating multidrug-resistant Pseudomonas aeruginosa.

Authors:  Meher Rizvi; Junaid Ahmad; Fatima Khan; Indu Shukla; Abida Malik; Hiba Sami
Journal:  Australas Med J       Date:  2015-01-31

7.  Importance of carbenicillin and gentamicin cross-resistant serotype 0:12 Pseudomonas aeruginosa in six Athens hospitals.

Authors:  N J Legakis; N Koukoubanis; K Malliara; D Michalitsianos; J Papavassiliou
Journal:  Eur J Clin Microbiol       Date:  1987-06       Impact factor: 3.267

8.  Modification of dienes mutual inhibition test for epidemiological characterization of Pseudomonas aeruginosa isolates.

Authors:  Erik L Munson; Michael A Pfaller; Gary V Doern
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

9.  Faucets as a reservoir of endemic Pseudomonas aeruginosa colonization/infections in intensive care units.

Authors:  D S Blanc; I Nahimana; C Petignat; A Wenger; J Bille; P Francioli
Journal:  Intensive Care Med       Date:  2004-07-15       Impact factor: 17.440

10.  Epidemiological risk factors for isolation of ceftriaxone-resistant versus -susceptible citrobacter freundii in hospitalized patients.

Authors:  Peter W Kim; Anthony D Harris; Mary-Claire Roghmann; J Glenn Morris; Arjun Strinivasan; Eli N Perencevich
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.